Milestone shares fell 20.6% after earnings, as investors likely focused on the gap between launch growth and the company’s need to cut costs: CARDAMYST prescriptions rose 50% quarter over quarter, but Milestone is reducing operating expenses by about 30% and restructuring its commercial organization. The transcript does not provide a revised sales outlook; the cost measures and leadership departures suggest the launch has yet to support the prior operating structure.
- CARDAMYST generated approximately 1,800 prescriptions in Q3, up 50% from Q2; cumulative prescriptions since launch reached approximately 3,400.
- About 750 unique healthcare providers prescribed the drug in Q3, a 16% increase from Q2; cumulative prescribers reached approximately 1,600.
- Formulary coverage rose to approximately two-thirds of commercially covered lives, from about 50% reported on the prior call.
- Milestone expects cost measures to reduce operating expenses by approximately 30%, with implementation targeted for completion by Q1 2027; it expects about $2 million in one-time charges.
- The company said the measures and an extended payment-in-kind interest period are expected to extend cash runway into late 2028, through the anticipated ReVeRA-301 Phase III readout in the second half of 2028.
Community Discussion